# A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

> **NCT05316220** · PHASE3 · WITHDRAWN · sponsor: **AbbVie**

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** Mesalamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05316220
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-09-15
- **Primary completion:** 2026-07-19
- **Final completion:** 2026-07-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** strategic considerations
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05316220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05316220, "A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05316220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*